Gastric Cancer Treatment: New Research on Adebrelimab Combination Therapy

Strategic Insights -

Researchers from Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital have recently conducted a study on the efficacy and safety of combining adebrelimab with apatinib and irinotecan for advanced gastric cancer refractory to PD-1 inhibitors. The single-arm, single-centre exploratory trial aimed to evaluate the combination therapy's potential in treating patients who have initially achieved response with PD-1 inhibitors but subsequently progressed.

Key Takeaways:

  • The study focused on evaluating the combination therapy of adebrelimab, apatinib, and irinotecan for advanced gastric cancer patients who have shown resistance to PD-1 inhibitors.
  • Adebrelimab, a PD-L1 inhibitor, demonstrated mechanistic advantages over PD-1 inhibitors, with clinical studies suggesting promising therapeutic potential when combined with other treatments.
  • The trial, conducted at Renji Hospital, enrolled 32 patients aged 18-75 years, who must have initially achieved partial response, complete response, or stable disease with progression-free survival (PFS) 3 months during prior immunotherapy.
  • The primary endpoint was the objective response rate with Clopper-Pearson 95% CI.
  • Secondary endpoints included disease control rate (95% CI), progression-free survival (PFS), overall survival (estimated by Kaplan-Meier method), and safety assessments.

Statistics:

  • 32 patients aged 18-75 years were enrolled in the single-arm, single-centre exploratory trial.
  • The study aimed to evaluate the objective response rate with Clopper-Pearson 95% CI as the primary endpoint.
  • The disease control rate (95% CI) and overall survival (estimated by Kaplan-Meier method) were also assessed as secondary endpoints.

Sources:

  • NewsRx. Research from Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital Yields New Findings on Gastric Cancer (Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective ...). Immunotherapy Weekly. June 18, 2025; p 1350.
  • Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective advanced-stage gastric cancer: study protocol for a single-arm, single-centre, exploratory trial. BMJ Open, 2025, 15(6). (BMJ Open - http://bmjopen.bmj.com/). The publisher for BMJ Open is BMJ Publishing Group. A free version of this journal article is available at https://doi-org.sdpl.idm.oclc.org/10.1136/bmjopen-2024-089286.